Inarigivir soproxil
As of the edition of 20 October 2026, Inarigivir soproxil is a small molecule: stopped in 2021; acts on NOD2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2021
- Kind
- Small molecule
- Registered trials
- 5, 4 stopped early
- Disease areas
- Digestive system; Infections; Immune system; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route A because of this drug.
Companies on route A for this drug
In the product2 companies are on route A because of Inarigivir soproxil.
See the 2 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| NOD2 | Nucleotide-binding oligomerization domain-containing protein 2 | Q9HC29 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 4 | 0 | 0 | 4 |
| All trials | 5 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Gilead Sciences | Lead sponsor of trials | 2018 to now |
| invoX Pharma | Lead sponsor of trials | 2019 to now |